Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01548378
Other study ID # NL003CLI-II
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date March 2012
Est. completion date June 2014

Study information

Verified date January 2020
Source Beijing Northland Biotech. Co., Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate whether intramuscular injections of NL003 into the calf is safe and effective in the treatment of critical limb ischemia


Description:

Management of CLI process consumes a significant amount of healthcare resources,and the new therapeutic approaches are required.

Hepatocyte growth factor (HGF) has been shown to be a potent angiogenic growth factor stimulating the growth of endothelial cells and migration of vascular smooth muscle cells. Because of its pluripotent capabilities, increasing the availability of HGF in ischemic tissues to achieve therapeutic angiogenesis has been a growing area of research.

This study will use NL003, which is a DNA plasmid that contains novel genomic cDNA hybrid human HGF coding sequence (HGF-X7) expressing two isoforms of HGF, HGF 728 and HGF 723. As there are currently no approved drugs that can reverse CLI and as most patients have exhausted surgical and endovascular intervention options, inducing angiogenesis in the affected limb with NL003 may result in an increase in tissue perfusion, which, in turn improve wound healing, reduce pain and improve limb salvage rates.


Recruitment information / eligibility

Status Completed
Enrollment 200
Est. completion date June 2014
Est. primary completion date June 2014
Accepts healthy volunteers No
Gender All
Age group 30 Years to 80 Years
Eligibility Inclusion Criteria:

- Male or female, between 30 and 80years of age

- Diagnosis of critical limb ischemia(ASO?TAO?DAO),Rutherford Class 4 or 5, including:

- A resting ankle systolic pressure of = 70 mmHg in the affected limb; or

- A resting toe systolic pressure of = 50 mmHg in the affected limb; or

- For patients in which measurement of ankle systolic pressure is not feasible , TcPO2 = 30mmHg; Only unilateral affected limb receive treatment?

- Significant stenosis (= 75%) of one or more of the following arteries:

superficial femoral, popliteal as verified by angiography(DSA?CTA?MRA) within 12 months prior to enrollment

- Be willing to maintain current drug therapy for peripheral arterial disease throughout the course of the study

- Be willing to maintain ulcer treatment

- Be willing to infertility throughout the course of the study

- If the subject is of child-bearing potential, she must have a negative urine pregnancy test result prior to study enrollment

- Tumor screening result is no clinic meaning,including:

- Signing the informed consent document prior to being subjected to any study related procedures

Exclusion Criteria:

- Subjects who have undergone a successful revascularization procedure or sympathectomy within 12 weeks prior to study entry.

- Acute advanced CLI

- Subjects that will require an amputation in the target leg within 4 weeks, or significant stenosis (= 75%) of Aortoiliac

- Subjects with evidence of active infection or deep ulceration exposing bone or tendon in the extremity planned for treatment

- Heart Failure with a NYHA classification of III or IV

- Stroke?myocardial infarction or unstable angina within last 3 months

- Uncontrolled hypertension defined as sustained systolic blood pressure (SBP) > 180 mmHg or diastolic BP (DBP) > 110 mmHg

- Ophthalmologic conditions pertinent to proliferative retinopathy or conditions that preclude standard ophthalmologic examination

- Can not correctly describe the symptoms and feeling

- Subjects with advanced liver disease including decompensated cirrhosis, jaundice, ascites or bleeding varices

- Subjects currently receiving immunosuppressive medications chemotherapy, or radiation therapy

- Positive HIV,active Hepatitis B(determined by HBsAb\ HBcAb\HBsAg) or C infection

- Specific laboratory values at Screening including: Hemoglobin < 8.0 g/dL, WBC < 3,000 cells per microliter, platelet count <75,000/mm3, AST and/or ALT > 3 times the upper limit of normal or any other clinically significant lab abnormality which in the opinion of the investigator should be exclusionary

- Elevated PSA unless prostate cancer has been excluded

- Patients with a recent history (< 5 years) of or new screening finding of malignant neoplasm except basal cell carcinoma or squamous cell carcinoma of the skin (if excised and no evidence of recurrence); patients with family history of colon cancer in any first degree relative are excluded unless they have undergone a colonoscopy in the last 12 months with negative findings

- Subjects requiring > 100 mg daily of acetylsalicylic acid,COX-2 inhibitor drug(s) or high dose steroids (excepting inhaled steroids)

- Subjects with any co- morbid conditions likely to interfere with assessment of safety or efficacy or with an estimated life expectancy of less than 12 months

- History of drug or alcohol abuse / dependence in the past 12 months

- Use of an investigational drug or treatment in past 3 months

Study Design


Intervention

Genetic:
NL003
Day 0: 8mg of NL003 (32 injections of 0.5ml of NL003) Day 14: 8mg of NL003 (32 injections of 0.5ml of NL003) Day 28: 8mg of NL003 (32 injections of 0.5ml of NL003)
NL003
Day 0: 6mg of NL003 (24 injections of 0.5ml of NL003) and 4ml normal saline(8 injections) Day 14: 6mg of NL003 (24 injections of 0.5ml of NL003) and 4ml normal saline(8 injections) Day 28: 6mg of NL003 (24 injections of 0.5ml of NL003) and 4ml normal saline(8 injections)
NL003
Day 0: 4mg of NL003 (16 injections of 0.5ml of NL003) and 8ml normal saline(16 injections) Day 14: 4mg of NL003 (16 injections of 0.5ml of NL003) and 8ml normal saline(16 injections) Day 28: 4mg of NL003 (16 injections of 0.5ml of NL003) and 8ml normal saline(16 injections)
Other:
Normal Saline
Day 0: 16ml of Normal Saline (32 injections ) Day 14: 16ml of Normal Saline (32 injections ) Day 28: 16ml of Normal Saline (32 injections )

Locations

Country Name City State
China Beijing Shijitan Hospital Beijing Beijing
China Peking Union Medical College Hospital Beijing Beijing
China The General Hospital of the People's Liberation Army Beijing Beijing
China Xuanwu Hospital Capital Medical University Beijing Beijing
China First Hospital of Jilin University Changchun Jilin
China The Second Xiangya Hospital of Central South University Changsha Hunan
China The Second Hospital of Dalian Medical University Dalian Liaoning
China Nanjing Drum Tower Hospital Nanjing Jiangsu
China Wuhan Union Hospital Wuhan Hubei

Sponsors (1)

Lead Sponsor Collaborator
Beijing Northland Biotech. Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary The difference in ulcer area between baseline and the D180. Rutherford 5 only Day180
Primary The difference in pain level between baseline and the D180 as determined by VAS Day 180
Secondary Change in tissue oxygenation (TcPO2) from baseline to D180 Day0?14?28?60?90?180
Secondary Difference in percentage of pain level decreased by 50% determined by VAS from baseline to D180 Day0?14?28?60?90?180
Secondary Difference in percentage of ulcer area decreased by 50% from baseline to D180 Day0?14?28?60?90?180
Secondary Difference in ABI and TBI from baseline to D180 Day0?14?28?60?90?180
Secondary Difference in QOL score (VascuQol) from baseline to D180 Day0?14?28?60?90?180
Secondary Percentage of ulcer complete healing Day180
Secondary Situation of ulcer healing Day180
Secondary Ulcer healing after gangrene treatment Day180
Secondary Major amputation rate Day180
See also
  Status Clinical Trial Phase
Recruiting NCT05335525 - Post-market Clinical Investigation of the Angio-Seal™ VIP VCD (ANGIO-SEAL CLOSE)
Active, not recruiting NCT01903044 - Safety and Efficacy of Autologous Bone Marrow Stem Cells for Lower Extremity Ischemia Treating Phase 1/Phase 2
Completed NCT02271529 - Zilver PTX Delivery System N/A
Completed NCT02228564 - BARD® Study of LIFESTREAM™ Balloon Expandable Covered Stent Treating Iliac Arterial Occlusive Disease N/A
Recruiting NCT02054871 - RCT to Evaluate the Renal Protective Effects of Remote Ischaemic Preconditioning in Peripheral Angioplasty N/A
Completed NCT00822172 - Evaluation of Cilostazol in Combination With L-Carnitine Phase 4
Completed NCT00574782 - Evaluation of the Efficacy of Rosuvastatin in Daily Practice in Untreated High Risk Patients (CHALLENGE) N/A
Completed NCT00029991 - Extract of Ginkgo Biloba (EGB 761) and Vascular Function Phase 1/Phase 2
Completed NCT01355406 - Evaluation of Safety and Efficacy of the FlexStent® Femoropopliteal Self-Expanding Stent System N/A
Recruiting NCT05804097 - Does Increasing Oxygen Nurture Your Symptomatic Ischemic Ulcer Sufficiently? Phase 4
Recruiting NCT03638115 - The VaSecure BTK Study N/A
Active, not recruiting NCT03241459 - Safety and Efficacy of the SurVeil™ Drug-Coated Balloon N/A
Active, not recruiting NCT01661231 - Study to Determine the Performance of the Astron and Pulsar-18 Stents in Europe N/A
Completed NCT01722877 - JetStream (JS) Atherectomy in Femoropopliteal In-Stent Restenotic Lesions N/A
Completed NCT01444378 - Absolute Pro® MOMENTUM™ N/A
Completed NCT00753337 - The ACTIVE (Use of the Assurant® Cobalt Iliac Stent System in the Treatment of Iliac Vessel Disease) Study N/A
Completed NCT00538226 - Evaluation of the Effect of the Flowaid Device in Increasing Local Circulation in the Leg Phase 1
Completed NCT00593385 - Atrium iCAST Iliac Stent Pivotal Study N/A
Recruiting NCT00385385 - RESTORE-IT-Study of Rifalazil in Chlamydia Pneumoniae Seropositive Patients With a History of Atherosclerotic Disease Phase 2
Completed NCT00392509 - ALD-301 for Critical Limb Ischemia, Randomized Trial Phase 1/Phase 2

External Links